Solventum Corporation/$SOLV

Solventum jumps after beating Q3 EPS and revenue estimates and raising full-year sales growth and EPS guidance.
11 hours agoLightyear AI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Solventum Corporation

Solventum Corp is a healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer and patient needs. The company has four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company generates the majority of its revenue from the MedSurg segment, which provides wound care and surgical solutions that are intended to accelerate healing, prevent complications, and lower the total cost of care globally.

Ticker

$SOLV
Sector
Health

Primary listing

NYSE

Employees

22,000
Headquarters
Maplewood, United States
Website
www.solventum.com

SOLV Metrics

BasicAdvanced
$11B
30.34
$2.18
-
-

What the Analysts think about SOLV

Analyst ratings (Buy, Hold, Sell) for Solventum Corporation stock.

Bulls say / Bears say

Solventum beat analysts’ Q1 profit estimates with adjusted EPS of $1.34 compared to the $1.22 consensus, thanks to better-than-expected sales in the MedSurg segment (Reuters)
After its Q1 results, Solventum increased its full-year organic sales growth forecast to 1.5%–2.5%, reflecting management’s confidence in market momentum (Reuters)
On August 7, 2025, Solventum raised its full-year adjusted profit forecast after MedSurg segment sales rose 4.8% year-over-year to $1.22 billion, highlighting strength in its core surgical and infection prevention product lines (Reuters)
Adjusted diluted EPS in Q1 dropped 35.6% year-over-year to $1.34, indicating weaker profitability (SEC filing)
Q1 reported net sales increased only 2.6% year-over-year to $2.07 billion, showing weak sales growth (SEC filing)
The improvement in Health Information Systems segment operating margin was mainly due to temporary savings from the Solventum Way restructuring program, raising questions about how sustainable this is (SEC filing)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2025.

SOLV Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

SOLV Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SOLV

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs